{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T07:48:58Z","timestamp":1793346538711,"version":"4.5.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T00:00:00Z","timestamp":1768003200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T00:00:00Z","timestamp":1768003200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100014943","name":"Sarepta Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014943","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007013","name":"F. Hoffmann-La Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s40120-025-00879-8","type":"journal-article","created":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T06:28:52Z","timestamp":1768026532000},"page":"545-559","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Two-Year Outcomes Following Delandistrogene Moxeparvovec Treatment in Ambulatory Patients with Duchenne Muscular Dystrophy: Phase\u00a03 EMBARK Trial"],"prefix":"10.1007","volume":"15","clinical-trial-number":[{"clinical-trial-number":"nct05096221","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-3966-6303","authenticated-orcid":false,"given":"Jerry R.","family":"Mendell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Muntoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig M.","family":"McDonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenio M.","family":"Mercuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Ciafaloni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Komaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Leon-Astudillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9s","family":"Nascimento","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Crystal","family":"Proud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrike","family":"Schara-Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aravindhan","family":"Veerapandiyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig M.","family":"Zaidman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Furgerson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Preeti","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachael","family":"Potter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damon R.","family":"Asher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander P.","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol","family":"Reid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Hooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen O.","family":"Torre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianna","family":"Manfrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise R.","family":"Rodino-Klapac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,10]]},"reference":[{"key":"879_CR1","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/s41572-021-00248-3","volume":"7","author":"D Duan","year":"2021","unstructured":"Duan D, Goemans N, Takeda S, Mercuri E, Aartsma-Rus A. Duchenne muscular dystrophy. Nat Rev Dis Primers. 2021;7:13.","journal-title":"Nat Rev Dis Primers"},{"key":"879_CR2","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1016\/j.ymthe.2025.03.065","volume":"33","author":"NE Bengtsson","year":"2025","unstructured":"Bengtsson NE, Tasfaout H, Chamberlain JS. The road towards AAV-mediated gene therapy of Duchenne muscular dystrophy. Mol Ther. 2025;33:2035\u201351.","journal-title":"Mol Ther"},{"key":"879_CR3","unstructured":"US Food and Drug Administration. ELEVIDYS\u00ae Highlights of prescribing information. 2025. https:\/\/www.elevidyshcp.com\/pi. Accessed December 2025."},{"key":"879_CR4","doi-asserted-by":"crossref","unstructured":"Mendell J, Sahenk Z, Lehman K, et al. Assessment of systemic delivery of rAAVrh74.MHCK7.micro-dystrophin in children with Duchenne muscular dystrophy: a nonrandomized controlled trial. JAMA Neurol. 2020; 77:1121\u201331.","DOI":"10.1001\/jamaneurol.2020.1484"},{"key":"879_CR5","doi-asserted-by":"publisher","first-page":"1167762","DOI":"10.3389\/fcell.2023.1167762","volume":"11","author":"JR Mendell","year":"2023","unstructured":"Mendell JR, Shieh PB, McDonald CM, et al. Expression of SRP-9001 dystrophin and stabilization of motor function up to 2\u00a0years post-treatment with delandistrogene moxeparvovec gene therapy in individuals with Duchenne muscular dystrophy. Front Cell Dev Biol. 2023;11:1167762.","journal-title":"Front Cell Dev Biol"},{"key":"879_CR6","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1002\/ana.26755","volume":"94","author":"CM Zaidman","year":"2023","unstructured":"Zaidman CM, Proud CM, McDonald CM, et al. Delandistrogene moxeparvovec gene therapy in ambulatory patients (aged \u22654 to <8\u00a0years) with Duchenne muscular dystrophy: 1-year interim results from study SRP-9001-103 (ENDEAVOR). Ann Neurol. 2023;94:955\u201368.","journal-title":"Ann Neurol"},{"key":"879_CR7","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1038\/s41591-024-03304-z","volume":"31","author":"JR Mendell","year":"2024","unstructured":"Mendell JR, Muntoni F, McDonald C, et al. AAV gene therapy for Duchenne muscular dystrophy: the EMBARK phase\u00a03 randomized trial. Nat Med. 2024;31:332\u201341.","journal-title":"Nat Med"},{"key":"879_CR8","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.nmd.2022.02.009","volume":"32","author":"F Muntoni","year":"2022","unstructured":"Muntoni F, Signorovitch J, Sajeev G, et al. Real-world and natural history data for drug evaluation in Duchenne muscular dystrophy: suitability of the North Star Ambulatory Assessment for comparisons with external controls. Neuromuscul Disord. 2022;32:271\u201383.","journal-title":"Neuromuscul Disord"},{"key":"879_CR9","doi-asserted-by":"publisher","first-page":"e1381","DOI":"10.1212\/WNL.0000000000010170","volume":"95","author":"N Goemans","year":"2020","unstructured":"Goemans N, Signorovitch J, Sajeev G, et al. Suitability of external controls for drug evaluation in Duchenne muscular dystrophy. Neurology. 2020;95:e1381\u201391.","journal-title":"Neurology"},{"key":"879_CR10","unstructured":"US Food & Drug Administration. Considerations for the design and conduct of externally controlled trials for drug and biological products. 2023. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/considerations-design-and-conduct-externally-controlled-trials-drug-and-biological-products. Accessed October 2025."},{"key":"879_CR11","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1023\/A:1020363010465","volume":"2","author":"DB Rubin","year":"2001","unstructured":"Rubin DB. Using propensity scores to help design observational studies: application to the tobacco litigation. Health Serv Outcomes Res Methodol. 2001;2:169\u201388.","journal-title":"Health Serv Outcomes Res Methodol"},{"key":"879_CR12","unstructured":"ClinicalTrials.gov. NCT01603407: Finding the optimum regimen for Duchenne muscular dystrophy (FOR-DMD). Bethesda, MD: National Library of Medicine (US). https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01603407. Accessed March 2025."},{"key":"879_CR13","unstructured":"ClinicalTrials.gov. NCT01753804: A prospective natural history study of progression of subjects with Duchenne muscular dystrophy. 2025. https:\/\/clinicaltrials.gov\/study\/NCT01753804?intr=NCT01753804&rank=1. Accessed March 2025."},{"key":"879_CR14","unstructured":"ClinicalTrials.gov. NCT00468832: Longitudinal study of the natural history of Duchenne muscular dystrophy (DMD). 2016. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00468832. Accessed March 2025."},{"key":"879_CR15","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1002\/mus.24163","volume":"50","author":"C Spurney","year":"2014","unstructured":"Spurney C, Shimizu R, Morgenroth LP, Kolski H, Gordish-Dressman H, Clemens PR. Cooperative International Neuromuscular Research Group Duchenne Natural History Study demonstrates insufficient diagnosis and treatment of cardiomyopathy in Duchenne muscular dystrophy. Muscle Nerve. 2014;50:250\u20136.","journal-title":"Muscle Nerve"},{"key":"879_CR16","doi-asserted-by":"crossref","unstructured":"Mendell JR, Muntoni F, McDonald CM, et al. Delandistrogene moxeparvovec in Duchenne muscular dystrophy: long-term EMBARK 2-year functional outcomes, safety, and micro-dystrophin expression. The 30th Annual International Congress of the World Muscle Society (WMS); 2025 October 7\u201311, 2025; Vienna, Austria.","DOI":"10.1016\/j.nmd.2025.105861"},{"key":"879_CR17","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1111\/dmcn.15176","volume":"64","author":"AA Zambon","year":"2022","unstructured":"Zambon AA, Ayyar Gupta V, Ridout D, et al. Peak functional ability and age at loss of ambulation in Duchenne muscular dystrophy. Dev Med Child Neurol. 2022;64:979\u201388.","journal-title":"Dev Med Child Neurol"},{"key":"879_CR18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0151445","volume":"11","author":"ES Mazzone","year":"2016","unstructured":"Mazzone ES, Coratti G, Sormani MP, et al. Timed rise from floor as a predictor of disease progression in Duchenne muscular dystrophy: an observational study. PLoS ONE. 2016;11:e0151445.","journal-title":"PLoS ONE"},{"key":"879_CR19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0304099","volume":"19","author":"CM McDonald","year":"2024","unstructured":"McDonald CM, Signorovitch J, Mercuri E, et al. Functional trajectories before and after loss of ambulation in Duchenne muscular dystrophy and implications for clinical trials. PLoS ONE. 2024;19:e0304099.","journal-title":"PLoS ONE"},{"key":"879_CR20","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/S1474-4422(18)30024-3","volume":"17","author":"DJ Birnkrant","year":"2018","unstructured":"Birnkrant DJ, Bushby K, Bann CM, et al. Diagnosis and management of Duchenne muscular dystrophy, Part\u00a01: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management. Lancet Neurol. 2018;17:251\u201367.","journal-title":"Lancet Neurol"},{"key":"879_CR21","unstructured":"Mercuri E, Asher D, Ding K, et al. Analytical framework for assessment of long-term efficacy of therapies for Duchenne Muscular dystrophy using external controls. Muscular Dystrophy Association (MDA) Clinical and Scientific Conference; 16\u201319 March; Dallas, TX, USA 2025. Available from: https:\/\/www.mdaconference.org\/abstract-library\/analytical-framework-for-assessment-of-long-term-efficacy-of-therapies-for-duchenne-muscular-dystrophy-using-external-controls\/."},{"key":"879_CR22","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1002\/mus.27955","volume":"69","author":"JR Mendell","year":"2024","unstructured":"Mendell JR, Sahenk Z, Lehman KJ, et al. Long-term safety and functional outcomes of delandistrogene moxeparvovec gene therapy in patients with Duchenne muscular dystrophy: a phase\u00a01\/2a nonrandomized trial. Muscle Nerve. 2024;69:93\u20138.","journal-title":"Muscle Nerve"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-025-00879-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-025-00879-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-025-00879-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T12:08:10Z","timestamp":1772798890000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-025-00879-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,10]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["879"],"URL":"https:\/\/doi.org\/10.1007\/s40120-025-00879-8","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,10]]},"assertion":[{"value":"10 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Jerry R. Mendell\u2019s affiliation at the time of part\u00a01 of EMBARK was Center for Gene Therapy, Nationwide Children\u2019s Hospital, Columbus, OH, USA (currently employed by Sarepta Therapeutics, Inc.); Jerry R. Mendell\u2019s affiliation at the time of part\u00a02 of EMBARK and current affiliation is Sarepta Therapeutics, Inc., Cambridge, MA, USA. Jerry R. Mendell received study funding from Sarepta Therapeutics, Inc. while at Nationwide Children\u2019s Hospital at the time of the study and is currently an employee of Sarepta Therapeutics, Inc. Jerry R. Mendell is a co-inventor of AAVrh74.MHCK7.micro-dys technology. Francesco Muntoni\u00a0has received honoraria and grants from Sarepta Therapeutics, Inc. for participating at symposia and advisory boards and is involved as an investigator in Sarepta Therapeutics, Inc. clinical trials. He reports participation in advisory boards for Novartis, F. Hoffmann-La Roche Ltd, Edgewise Therapeutics, Dyne Therapeutics, Pfizer, PTC Therapeutics, and Italfarmaco. Craig M. McDonald reports grants from Capricor Therapeutics, Catabasis, Edgewise Therapeutics, Epirium Bio, Italfarmaco, Pfizer, PTC Therapeutics, Santhera Pharmaceuticals, and Sarepta Therapeutics, Inc. and has a consultancy\/advisory role with Biomarin, Capricor Therapeutics, Catalyst, Edgewise Therapeutics, Italfarmaco, PTC Therapeutics, F. Hoffmann-La Roche Ltd., Santhera Pharmaceuticals and Sarepta Therapeutics, Inc. He has received honoraria from PTC Therapeutics and Sarepta Therapeutics, Inc. Eugenio M. Mercuri has received fees from AveXis, Biogen, and F. Hoffmann-La Roche Ltd. Emma Ciafaloni\u00a0has received honoraria from Sarepta Therapeutics, Inc. for participating on advisory boards and research and\/or grant support from the Centers for Disease Control and Prevention, CureSMA, the Muscular Dystrophy Association, the National Institutes of Health, Orphazyme, the Patient-Centered Outcomes Research Institute, Parent Project Muscular Dystrophy, PTC Therapeutics, Santhera\u00a0Pharmaceuticals, Sarepta Therapeutics, Inc., and the US Food and Drug Administration. Hirofumi Komaki has received grants from Sarepta Therapeutics, Inc., Pfizer, PTC Therapeutics, Taiho Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Nippon Shinyaku Co., Ltd., and Kaneka Corporation. Hirofumi Komaki has received fees from Sarepta Therapeutics, Inc., Pfizer, PTC Therapeutics, Chugai Pharmaceutical Co., Nippon Shinyaku Co., and Kaneka Corporation. Carmen Leon-Astudillo is an investigator in Sarepta Therapeutics, Inc. clinical trials and a sub-investigator in studies sponsored by Pfizer, SolidBioSciences, Edgewise Therapeutics, Italfarmaco, and Genentech\/Roche. Andr\u00e9s Nascimento has received fees from AveXis, Biogen, and F. Hoffmann-La Roche Ltd. Crystal Proud participates on an advisory board and is a consultant for Biogen, Sarepta Therapeutics, Inc., AveXis\/Novartis Gene Therapies, Genentech\/Roche, and Scholar Rock; serves as a speaker for Biogen; and is a principal investigator of studies sponsored by AveXis\/Novartis Gene Therapies, AMO Pharma, Astellas, Biogen, CSL Behring, Fibrogen, PTC Therapeutics, Pfizer, Sarepta Therapeutics, Inc., and Scholar Rock. Ulrike Schara-Schmidt has received honoraria for counseling and participating in invited talks from Sarepta Therapeutics, Inc., and F. Hoffmann-La Roche Ltd. Aravindhan Veerapandiyan has a consultancy\/advisory role with AMO Pharma, AveXis, Biogen, Edgewise Therapeutics, FibroGen, Novartis, Pfizer, PTC Therapeutics, Sarepta Therapeutics, Inc., UCB Pharma, Catalyst, and Scholar Rock; has received research funding from AMO Pharma, Capricor Therapeutics, Edgewise Therapeutics, FibroGen, the Muscular Dystrophy Association, Novartis, Parent Project Muscular Dystrophy, Pfizer, RegenxBio, and Sarepta Therapeutics, Inc.; and has other relationship(s) with MedLink Neurology for editorial services. Craig M. Zaidman has received research support from Biogen and Novartis and has served on an advisory board for Sarepta Therapeutics, Inc. Matthew Furgerson, Kai Ding, Preeti Singh, Rachael Potter, and Damon R. Asher are employees of Sarepta Therapeutics, Inc. and may have stock options. Kai Ding\u2019s affiliation at the time of part\u00a01 of EMBARK was Sarepta Therapeutics, Inc., Cambridge, MA, USA; Kai Ding is no longer employed by Sarepta Therapeutics, Inc. Alexander P. Murphy, Carol Reid, Gregory Hooper and Carmen O. Torre are employees of Roche Products Ltd and may have stock options in F. Hoffmann-La Roche Ltd. Marianna Manfrini is an employee of F. Hoffmann-La Roche Ltd and may have stock options. Louise R. Rodino-Klapac is an employee of Sarepta Therapeutics, Inc. and may have stock options. In addition, she is a co-inventor of AAVrh74.MHCK7.micro-dys technology.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The EMBARK study design, including patient selection, ethics declarations (including a full list of institutional review boards and ethics committees), and descriptions of the gene therapy, has been previously published in full [\n                      \n                      ]. This trial was conducted in compliance with Good Clinical Practice guidelines and the Declaration of Helsinki. The institutional review board and ethics committee at each site approved the trial protocol and all amendments. Details of all institutional review boards and ethics committees are available in the Supplementary Material. Upon reasonable request, the trial protocol is available from the corresponding author. The study\u2019s primary analysis was carried out after all patients completed part\u00a01 and these findings have been published [\n                      \n                      ]. All authors were involved in the study design, data collection, analyses, and interpretation, as well as the writing, reviewing, and approval of the manuscript and jointly agreed to its publication [\n                      \n                      ]. The sponsor was responsible for confirming the final trial design, protocol, and conduct, along with database maintenance, data analyses, and accuracy of the data [\n                      \n                      ]. All authors collected and had full access to the data, and attested to their accuracy and completeness in accordance with the trial protocol [\n                      \n                      ]. Parent(s)\/legal guardian(s) provided informed consent and, when applicable, patients\u2019 assent was obtained. Safety, efficacy, data quality, and study integrity continue to be monitored by an independent data monitoring committee [\n                      \n                      ].","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}